Securities Purchase Agreement



 Exhibit 10.1 
  
 SECURITIES PURCHASE AGREEMENT 
  

SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 12, 2004, by and among eDiets.com, Inc., a Delaware
corporation, with headquarters located at 3801 W. Hillsboro Boulevard, Deerfield Beach, Florida 33442 (the “Company”), Mr. David R. Humble (the “Selling Shareholder”) and the investors listed on the Schedule of
Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). 
  
 WHEREAS: 
  
 A. The Company, the Selling Shareholder and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities
registration afforded by Section 4 of the Securities Act of 1933, as amended (the “1933 Act”), and in the case of sales by the Company Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States
Securities and Exchange Commission (the “SEC”) under Section 4(2) of the 1933 Act; 
  
 B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) that aggregate number of
shares of the common stock, $.001 par value per share, of the Company (the “Common Stock”), set forth opposite such Buyer’s name in column (3) on the Schedule of Buyers (which aggregate amount for all Buyers together shall be
1,600,000 shares of Common Stock and shall collectively be referred to herein as the “Primary Shares”) and (ii) a right to acquire up to that number of additional shares of Common Stock set forth opposite such Buyer’s name in
column (4) on the Schedule of Buyers (the “Additional Investment Rights”), in substantially the form attached hereto as Exhibit A (as exercised, collectively, the “Additional Investment Right Shares”);

  
 C. Each Buyer wishes to purchase, and the Selling Shareholder
wishes to sell, upon the terms and conditions stated in this Agreement, that aggregate number of shares of Common Stock set forth opposite such Buyer’s name in column (5) on the Schedule of Buyers (which aggregate amount for all Buyers together
shall be 600,000 shares of Common Stock, and shall collectively be referred to herein as the “Secondary Shares”; the Primary Shares and the Secondary Shares are referred to herein as the “Common Shares”);

  
 D. Contemporaneously with the execution and delivery of this
Agreement, the Company and the Buyers are executing and delivering a Registration Rights Agreement, substantially in the form attached hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company
has agreed to provide certain registration rights with respect to the Common Shares, and the Additional Investment Right Shares under the 1933 Act and the rules and regulations promulgated thereunder, and applicable state securities laws.

  
 E. The Common Shares, the Additional Investment Rights and the
Additional Investment Right Shares collectively are referred to herein as the “Securities”. 







 NOW, THEREFORE, the Company, the Selling Shareholder and each Buyer hereby agree as follows:

  
 1. PURCHASE AND SALE OF COMMON SHARES AND ADDITIONAL
INVESTMENT RIGHTS. 
  
 a. Purchase of Common Shares and
Additional Investment Rights. 
  
 Subject to the satisfaction
(or waiver) of the conditions set forth in Sections 6 and 7 below, the Company shall issue and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company on the Closing Date (as defined below), the number of
Primary Shares as is set forth opposite such Buyer’s name in column (3) on the Schedule of Buyers, along with the Additional Investment Rights to acquire up to that number of Additional Investment Right Shares as is set forth opposite such
Buyer’s name in column (4) on the Schedule of Buyers. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the Selling Shareholder shall sell to each Buyer, and each Buyer severally, but not jointly,
agrees to purchase from the Selling Shareholder on the Closing Date, the number of Secondary Shares as is set forth opposite such Buyer’s name in column (5) on the Schedule of Buyers. These transactions (the “Closing”) shall
occur on the Closing Date at the offices of Schulte Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022. 
  
 b. Purchase Price. The purchase price for the Common Shares and related Additional Investment Rights to be purchased by each Buyer at the Closing
shall be the amount set forth opposite such Buyer’s name in column (6) of the Schedule of Buyers (the “Purchase Price”), which shall be equal to the amount of $4.40 per Common Share. 
  
 c. Closing Date. The date and time of the Closing (the
“Closing Date”) shall be 10:00 a.m., New York City Time, on the date hereof after notification of satisfaction (or waiver) of the conditions to the Closing set forth in Sections 6 and 7 below (or such later date as is mutually
agreed to by the Company and each Buyer). 
  
 d. Form of
Payment. On the Closing Date, (i) each Buyer shall pay its Purchase Price to the Company for the Common Shares and the Additional Investment Rights to be issued and sold to such Buyer at the Closing, by wire transfer of immediately available
funds in accordance with the Company’s written wire instructions; (ii) the Company shall deliver to the Selling Shareholder the aggregate purchase price paid by the Buyers for the Secondary Shares pursuant to Section 1(d)(i) hereof, by wire
transfer of immediately available funds in accordance with the Selling Shareholder’s written wire instructions, and (iii) the Company shall deliver to each Buyer (A) on behalf of itself and on behalf of the Selling Shareholder, one or more
stock certificates, free and clear of all restrictive and other legends (except as expressly provided in Section 2(g) hereof), evidencing the number of Common Shares such Buyer is purchasing as is set forth opposite such Buyer’s name in columns
(3) and (5) of the Schedule of Buyers, duly executed on behalf of the Company and registered on the transfer books of the Company or its agent in the name of such Buyer and (B) an Additional Investment Right pursuant to which such Buyer shall have
the right to acquire such number of Additional Investment Right Shares as is set forth opposite such Buyer’s name in column (4) of the Schedule of Buyers, in all cases duly executed on behalf of the Company and registered in the name of such
Buyer. 
  

 -2- 








 2. BUYER’S REPRESENTATIONS AND WARRANTIES. 
  
 Each Buyer represents and warrants with respect to only itself that:

  
 a. No Public Sale or Distribution. Such Buyer is (i)
acquiring the Common Shares and the Additional Investment Rights and (ii) upon exercise of the Additional Investment Rights will acquire the Additional Investment Right Shares issuable upon exercise thereof, in the ordinary course of business for
its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under the 1933 Act and such Buyer does not have a present arrangement to effect
any distribution of the Securities to or through any person or entity; provided, however, that by making the representations herein, such Buyer does not agree to hold any of the Securities for any minimum or other specific term and
reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act. 
  
 b. Accredited Investor Status. Such Buyer is, and upon exercise of any Additional Investment Right will be, an “accredited investor” as
that term is defined in Rule 501(a) of Regulation D. 
  
 c.
Reliance on Exemptions. Such Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company
and the Selling Shareholder are relying in part upon the truth and accuracy of, and such Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Buyer set forth herein in order to
determine the availability of such exemptions and the eligibility of such Buyer to acquire the Securities. 
  
 d. Information. Such Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of
the Company and materials relating to the offer and sale of the Securities which have been requested by such Buyer. Such Buyer and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such inquiries nor
any other due diligence investigations conducted by such Buyer or its advisors, if any, or its representatives shall modify, amend or affect such Buyer’s right to rely on the Company’s and the Selling Shareholder’s representations and
warranties contained herein. Such Buyer understands that its investment in the Securities involves a high degree of risk and is able to afford a complete loss of such investment. Such Buyer has sought such accounting, legal and tax advice as it has
considered necessary to make an informed investment decision with respect to its acquisition of the Securities. 
  
 e. No Governmental Review. Such Buyer understands that no United States federal or state agency or any other government or governmental agency has
passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities. 
  

 -3- 








 f. Transfer or Resale. Such Buyer understands that except as provided in the Registration Rights
Agreement: (i) the Securities have not been and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) such Buyer
shall have delivered to the Company an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such
registration, or (C) such Buyer provides the Company with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 promulgated under the 1933 Act, as amended (or a successor rule thereto) (collectively,
“Rule 144”); (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and further, any resale of the Securities under circumstances in which the seller (or the Person (as
defined in Section 3(r)) through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC
thereunder; and (iii) neither the Company nor any other Person is under any obligation to register the Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding
the foregoing, the Securities may be pledged in connection with a bona fide margin account or other loan secured by the Securities and such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder,
and no Buyer effecting a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document, including, without limitation,
this Section 2(f). 
  
 g. Legends. Such Buyer understands
that the certificates or other instruments representing the Common Shares and the Additional Investment Rights and, until such time as the resale of the Common Shares and the Additional Investment Right Shares have been registered under the 1933 Act
as contemplated by the Registration Rights Agreement, the stock certificates representing the Additional Investment Right Shares, except as set forth below, shall bear any legend as required by the “blue sky” laws of any state and a
restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such stock certificates): 
  
 [NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED
UNDER SAID 
  

 -4- 








 ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE
SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. 
  
 h. Validity; Enforcement. This Agreement and the Registration Rights Agreement have been duly and validly authorized, executed and delivered on
behalf of such Buyer and shall constitute the legal, valid and binding obligations of such Buyer enforceable against such Buyer in accordance with their respective terms, except as such enforceability may be limited by general principles of equity
or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies. 
  
 i. No Conflicts. The execution, delivery and performance by such Buyer
of this Agreement and the Registration Rights Agreement and the consummation by such Buyer of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Buyer or (ii) conflict with, or
constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such
Buyer is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts,
defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to perform its obligations hereunder. 
  
 j. Residency. Such Buyer is a resident of that jurisdiction specified
below its address on the Schedule of Buyers. 
  
 3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND THE SELLING SHAREHOLDER. 
  
 (i) The Company represents and warrants to each of the Buyers that: 
  
 a. Organization and Qualification. Each of the Company and its “Subsidiaries” (which for purposes of this Agreement means any
entity in which the Company, directly or indirectly, owns a majority of the capital stock or holds a majority equity or similar interest) are corporations duly organized and validly existing in good standing under the laws of the jurisdiction in
which they are incorporated, and have the requisite corporate power and authorization to own their properties and to carry on their business as now being conducted. Each of the Company and its Subsidiaries is duly qualified as a foreign corporation
to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good
standing would not have a Material Adverse Effect. As used in this Agreement, “Material Adverse Effect” means any material adverse effect on the business, properties, assets, operations, results of operations, condition (financial
or 
  

 -5- 








 otherwise) or prospects of the Company and its Subsidiaries, taken as a whole, or on the transactions contemplated hereby
and the other Transaction Documents (as defined below) or by the agreements and instruments to be entered into in connection herewith or therewith, or on the authority or ability of the Company to perform its obligations under the Transaction
Documents. The Company has no Subsidiaries except as set forth on Schedule 3(a). 
  
 b. Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement, the Registration Rights Agreement, the
Irrevocable Transfer Agent Instructions (as defined in Section 5(b)), the Additional Investment Rights and each of the other agreements entered into by the parties hereto in connection with the transactions contemplated by this Agreement
(collectively, the “Transaction Documents”) and to issue the Securities in accordance with the terms hereof and thereof. The execution and delivery of the Transaction Documents by the Company and the consummation by the Company of
the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Common Shares and the Additional Investment Rights and the reservation for issuance and the issuance of the Additional Investment Right Shares
issuable upon exercise thereof have been duly authorized by the Company’s Board of Directors and no further consent or authorization is required by the Company, its Board of Directors or its stockholders. This Agreement and the other
Transaction Documents have been duly executed and delivered by the Company, and constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such
enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and
remedies. 
  
 c. Issuance of Securities. The Common Shares
and the Additional Investment Rights are duly authorized and, upon issuance in accordance with the terms hereof, shall be validly issued and free from all taxes, liens and charges with respect to the issue thereof, and the Common Shares upon
issuance shall be fully paid and nonassessable with the holders being entitled to all rights accorded to a holder of Common Stock. As of the Closing Date, the Company shall have duly authorized and reserved for issuance a number of shares of Common
Stock which equals the number of Additional Investment Right Shares. The Company shall, so long as any of the Additional Investment Rights are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued
Common Stock, solely for the purpose of effecting the exercise of the Additional Investment Rights, 100% of the number of shares of Common Stock issuable upon exercise of the Additional Investment Rights. Upon exercise in accordance with the
Additional Investment Rights, the Additional Investment Right Shares will be validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof, with the holders being entitled to all rights
accorded to a holder of Common Stock. Assuming the accuracy of the representations and warranties of each of the Buyers in Section 2 hereof, the issuance by the Company of the Securities is exempt from registration under the 1933 Act. 
  
 d. No Conflicts. The execution, delivery and performance of the
Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Common Shares and Additional Investment Rights and reservation for
issuance and issuance of 
  

 -6- 








 the Additional Investment Right Shares) will not: (i) result in a violation of the Certificate of Incorporation (as
defined below) or Bylaws (as defined below) of the Company or any of its Subsidiaries, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any material agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or
decree (including federal and state securities laws and regulations and the rules and regulations of the Nasdaq SmallCap Market (the “Principal Market”)) applicable to the Company or any of its Subsidiaries or by which any property
or asset of the Company or any of its Subsidiaries is bound or affected; other than, in the case of clauses (ii) or (iii) above, such conflicts, defaults or violations which would not have, individually or in the aggregate, a Material Adverse
Effect. 
  
 e. Consents. The Company is not required to
obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its
obligations under or contemplated by the Transaction Documents, in each case in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the
preceding sentence have been obtained or effected on or prior to the Closing Date. The Company and its Subsidiaries are unaware of any facts or circumstances that might prevent the Company from obtaining or effecting any of the registration,
application or filings pursuant to the preceding sentence. The Company is not in violation of the listing requirements of the Principal Market and has no knowledge of any facts that would reasonably lead to delisting or suspension of the Common
Stock in the foreseeable future. 
  
 f. Acknowledgment
Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that each Buyer is acting solely in the capacity of arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby
and thereby and that no Buyer is (i) an officer or director of the Company, (ii) an “affiliate” of the Company (as defined in Rule 144) or (iii) to the knowledge of the Company, a “beneficial owner” of more than 10% of the Common
Stock (as defined for purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “1934 Act”)). The Company further acknowledges that no Buyer is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives or agents in connection with the Transaction Documents and the
transactions contemplated hereby and thereby is merely incidental to such Buyer’s purchase of the Securities. The Company further represents to each Buyer that the Company’s decision to enter into the Transaction Documents has been based
solely on the independent evaluation by the Company and its representatives. 
  
 g. No General Solicitation; Placement Agent’s Fees. Neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general
advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or brokers’ commissions
(other 
  

 -7- 








 than for persons engaged by any Buyer or its investment advisor) relating to or arising out of the transactions
contemplated hereby. The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any such claim. The Company
acknowledges that it has engaged Thomas Weisel Partners as placement agent (the “Agent”) in connection with the sale of the Securities. Other than the Agent, the Company has not engaged any placement agent or other agent in
connection with the sale of the Securities. 
  
 h. No
Integrated Offering. None of the Company, its Subsidiaries, any of their affiliates, and any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under
circumstances that would require registration of any of the Securities under the 1933 Act or cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the 1933 Act or any applicable stockholder
approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated. None of the Company, its Subsidiaries, their
affiliates and any Person acting on their behalf will take any action or steps referred to in the preceding sentence that would require registration of any of the Securities under the 1933 Act or cause the offering of the Securities to be integrated
with other offerings. 
  
 i. Application of Takeover
Protections. The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Certificate of Incorporation or the laws of the state of its incorporation which is or could become applicable to any Buyer as a result of the transactions contemplated by this Agreement, including,
without limitation, the Company’s issuance of the Securities and any Buyer’s ownership of the Securities. 
  
 j. SEC Documents; Financial Statements. Since January 1, 2003, the Company has timely filed all reports, schedules, forms, statements and other
documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing filed prior to the date hereof or prior to the date of the Closing, and all exhibits included therein and financial
statements and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the “SEC Documents”). The Company has delivered to the Buyers or their respective representatives true, correct and
complete copies of the SEC Documents not available on the EDGAR system. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated
thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all
material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles, consistently
applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim 
  

 -8- 








 statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all
material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). After
giving effect to the 8-K Filing (as defined below), no other information provided by or on behalf of the Company to the Buyers which is not included in the SEC Documents, including, without limitation, information referred to in Section 2(d) of this
Agreement, contains any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements therein, in the light of the circumstance under which they are or were made, not misleading. 
  
 k. Absence of Certain Changes. Except as disclosed in Schedule
3(k), since January 1, 2004, there has been no material adverse change and no material adverse development in the business, properties, operations, condition (financial or otherwise), results of operations or prospects of the Company or its
Subsidiaries. Except as disclosed in Schedule 3(k), since January 1, 2004, the Company has not (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate, in excess of $250,000 outside of the ordinary course of
business, or (iii) had capital expenditures, individually or in the aggregate, in excess of $1,000,000. The Company has not taken any steps to seek protection pursuant to any bankruptcy law nor does the Company have any knowledge or reason to
believe that its creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so. The Company is not as of the date hereof, and after giving effect to the
transactions contemplated hereby to occur at the Closing, will not be Insolvent (as defined below). For purposes of this Section 3(k), “Insolvent” means (i) the present fair saleable value of the Company’s assets is less than
the amount required to pay the Company’s total Indebtedness (as defined in Section 3(r)), (ii) the Company is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and
matured, (iii) the Company intends to incur or believes that it will incur debts that would be beyond its ability to pay as such debts mature or (iv) the Company has unreasonably small capital with which to conduct the business in which it is
engaged as such business is now conducted and is proposed to be conducted. 
  
 l. No Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has occurred or exists, or is contemplated to occur, with respect to the Company or its
Subsidiaries or their respective business, properties, prospects, operations or financial condition, that would be required to be disclosed by the Company under applicable securities laws on a registration statement on Form S-1 filed with the SEC
relating to an issuance and sale by the Company of its Common Stock and which has not been reflected in the SEC Documents or otherwise publicly announced. 
  
 m. Conduct of Business; Regulatory Permits. Neither the Company nor its Subsidiaries is in violation of any term of or in default under the
Certificate of Incorporation or Bylaws or their organizational charter or bylaws, respectively. Neither the Company nor any Subsidiary is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the
Company or its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except for possible violations which would not, individually or in the aggregate, have 
  

 -9- 








 a Material Adverse Effect. Without limiting the generality of the foregoing, the Company is not in violation of any of
the rules, regulations or requirements of the Principal Market and has no knowledge of any facts or circumstances that would reasonably lead to delisting or suspension of the Common Stock by the Principal Market in the foreseeable future. Since
February 17, 2004, (i) the Common Stock has been designated for quotation or listed on the Principal Market, (ii) trading in the Common Stock has not been suspended by the SEC or the Principal Market and (iii) the Company has received no
communication, written or oral, from the SEC or the Principal Market regarding the suspension or delisting of the Common Stock from the Principal Market. The Company and its Subsidiaries possess all certificates, authorizations and permits issued by
the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations or permits would not have, individually or in the aggregate, a
Material Adverse Effect, and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. 
  
 n. Foreign Corrupt Practices. Neither the Company, nor any of its
Subsidiaries, nor any director, officer, agent, employee or other Person acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful
contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in
violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or
employee. 
  
 o. Sarbanes-Oxley Act. The Company is in
compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date
hereof, except where such noncompliance would not have, individually or in the aggregate, a Material Adverse Effect. 
  
 p. Transactions With Affiliates. Except as set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2003, none of
the officers, directors or employees of the Company is presently a party to any transaction with the Company or any of its Subsidiaries (other than for ordinary course services as employees, officers or directors), including any contract, agreement
or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any such officer, director or employee or, to the knowledge of the
Company, any corporation, partnership, trust or other entity in which any such officer, director, or employee has a substantial interest or is an officer, director, trustee or partner. 
  
 q. Equity Capitalization. As of the date hereof, the authorized capital stock of the Company consists of (x)
50,000,000 shares of Common Stock, of which as of the date hereof, 18,678,741 shares are issued and outstanding, 2,893,241 shares are reserved for issuance pursuant to the Company’s employee incentive plan and other warrants outstanding and no
other shares are reserved for issuance pursuant to securities (other than the Additional Investment Rights) exercisable or exchangeable for, or convertible into, shares of Common 
  

 -10- 








 Stock, and (y) 1,000 shares of preferred stock, of which as of the date hereof, none are issued and outstanding. All of
such outstanding shares have been, or upon issuance will be, validly issued and are fully paid and nonassessable. There are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the
Securities. Except as set forth on Schedule 3(q) or reflected in the SEC Documents: (i) no shares of the Company’s capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or
permitted by the Company; (ii) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any
shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the
Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares of capital
stock of the Company or any of its Subsidiaries; (iii) there are no outstanding debt securities, notes, credit agreements, credit facilities or other agreements, documents or instruments evidencing Indebtedness (as defined in Section 3(r)) of the
Company or any of its Subsidiaries or by which the Company or any of its Subsidiaries is or may become bound; (iv) there are no financing statements securing obligations in any material amounts, either singly or in the aggregate, filed in connection
with the Company; (v) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act (except the Registration Rights Agreement); (vi) there
are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its
Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (vii) the Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement; and
(viii) the Company and its Subsidiaries have no liabilities or obligations required to be disclosed in the SEC Documents (as defined herein) but not so disclosed in the SEC Documents, other than those incurred in the ordinary course of the
Company’s or any Subsidiary’s respective businesses and which, individually or in the aggregate, do not or would not have a Material Adverse Effect. The Company has furnished or made available to the Buyer true, correct and complete copies
of the Company’s Certificate of Incorporation, as amended and as in effect on the date hereof (the “Certificate of Incorporation”), and the Company’s Bylaws, as amended and as in effect on the date hereof (the
“Bylaws”), and the terms of all securities convertible into, or exercisable or exchangeable for, Common Stock and the material rights of the holders thereof in respect thereto. 
  
 r. Indebtedness and Other Contracts. Except as disclosed in
Schedule 3(r) or in the SEC Documents, neither the Company nor any of its Subsidiaries (i) has any outstanding Indebtedness (as defined below), (ii) is a party to any contract, agreement or instrument, the violation of which, or default under
which, by the other party(ies) to such contract, agreement or instrument would result in a Material Adverse Effect, (iii) is in violation of any term of or in default under any contract, agreement or instrument relating to any Indebtedness, except
where such violations and defaults would not result, individually or in the aggregate, in a Material Adverse Effect, or (iv) is a party to any contract, agreement or instrument relating to any Indebtedness, the performance of which, in the judgment
of the 
  

 -11- 








 Company’s officers, has or is expected to have a Material Adverse Effect. Schedule 3(r)(i) provides a detailed
description of the material terms of any outstanding Indebtedness not described in the SEC Documents, none of which is secured. For purposes of this Agreement: (x) “Indebtedness” of any Person means, without duplication (A) all
indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase price of property or services (other than trade payables entered into in the ordinary course of business), (C) all reimbursement or payment
obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the
acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with the
proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar
arrangement which, in connection with generally accepted accounting principles, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or
for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets (including accounts and contract
rights) owned by any Person, even though the Person which owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations of others of
the kinds referred to in clauses (A) through (G) above; (y) “Contingent Obligation” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any indebtedness, lease, dividend
or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or
that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto; and (z) “Person” means an individual, a limited liability
company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof. 
  
 s. Absence of Litigation. Except as disclosed in the SEC Documents, there is no action, suit, proceeding or (to the knowledge of the Company)
inquiry or investigation before or by the Principal Market, any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company, the Common Stock
or any of its Subsidiaries or any of the Company’s or the Company’s Subsidiary’s officers or directors in their capacities as such. 
  
 t. Insurance. The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. Neither the Company nor any Subsidiary has been refused any insurance coverage sought or
applied for and neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be
necessary to continue its business at a cost that would not have a Material Adverse Effect. 
  

 -12- 








 u. Employee Relations. 
  
 (i) Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or employs any member
of a union. The Company and its Subsidiaries believe that their relations with their employees are good. No executive officer of the Company (as defined in Rule 501(f) of the 1933 Act) has notified the Company that such officer intends to leave the
Company or otherwise terminate such officer’s employment with the Company. No executive officer of the Company, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each such executive officer does not subject the Company or
any of its Subsidiaries to any liability with respect to any of the foregoing matters. 
  
 (ii) The Company and its Subsidiaries are in compliance with all federal, state, local and foreign laws and regulations respecting employment and employment practices, terms and conditions of employment and wages and
hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. 
  
 v. Title. The Company and its Subsidiaries do not own any real property. The Company and its Subsidiaries have good
and marketable title to all personal property owned by them which is material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value
of such property and do not interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries. Any real property and facilities held under lease by the Company and any of its Subsidiaries are held by
them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries. 
  
 w. Intellectual Property Rights. The Company and its Subsidiaries own
or possess adequate rights or licenses to use all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and
other intellectual property rights (“Intellectual Property Rights”) necessary to conduct their respective businesses as now conducted. Except as set forth in Schedule 3(w) or as described in the SEC Documents, (i) none of the
Company’s Intellectual Property Rights have expired or terminated, or are expected to expire or terminate within three years from the date of this Agreement; (ii) the Company does not have any knowledge of any infringement by the Company or its
Subsidiaries of Intellectual Property Rights of others; and (iii) there is no claim, action or proceeding being made or brought, or to the knowledge of the Company, being threatened, against the Company or any of its Subsidiaries regarding its
Intellectual Property Rights. The Company is unaware of any facts or circumstances which might give rise to any of the foregoing infringements or claims, actions or proceedings. The Company and its Subsidiaries have taken reasonable security
measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights. 
  

 -13- 








 x. Environmental Laws. The Company and its Subsidiaries (i) are in compliance with any and all
Environmental Laws (as hereinafter defined), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses, and (iii) are in compliance with all terms and
conditions of any such permit, license or approval where, in each of the foregoing clauses (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The term
“Environmental Laws” means all federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or
subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous
Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or
demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder. 
  
 y. Subsidiary Rights. The Company has the unrestricted right to vote, and (subject to limitations imposed by
applicable law) to receive dividends and distributions on, all capital securities of its Subsidiaries. 
  
 z. Tax Status. The Company and each of its Subsidiaries (i) has made or filed all federal and state income and all other tax returns, reports and
declarations required by any jurisdiction to which it is subject,(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except
those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of all accrued taxes for periods through the date hereof subsequent to the periods to which such returns, reports or declarations
apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. 
  
 aa. Internal Accounting and Disclosure Controls. The Company and each of its Subsidiaries maintain a system of
internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with generally accepted accounting principles and to maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general
or specific authorization and (iv) the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any difference. The Company
maintains disclosure controls and procedures (as such term is defined in Rule 13a-14 under the 1934 Act) that are effective in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the 1934
Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, 
  

 -14- 








 including, without limitation, controls and procedures designed in to ensure that information required to be disclosed by
the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to the Company’s management, including its principal executive officer or officers and its principal financial officer or officers, as
appropriate, to allow timely decisions regarding required disclosure. 
  
 bb. Disclosure. The Company confirms that, after giving effect to the 8-K Filing (as defined below), neither it nor any other Person acting on its behalf has provided any of the Buyers or their respective agents or counsel with any
information that constitutes or might constitute material, nonpublic information. The Company understands and confirms that each of the Buyers may rely on the foregoing representations in effecting transactions in securities of the Company. All
disclosure provided to the Buyers regarding the Company, its business and the transactions contemplated hereby, including the Schedules to this Agreement, furnished by or on behalf of the Company are true and correct and do not contain any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. No event or circumstance has occurred or
information exists with respect to the Company or any Subsidiary or either of its or their respective business, properties, prospects, operations or financial conditions, which, under applicable law, rule or regulation, requires public disclosure or
announcement by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the Company’s reports filed under the Exchange Act of 1934, as amended, are being incorporated into an effective registration
statement filed by the Company under the 1933 Act). The Company acknowledges and agrees that no Buyer makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in
Section 2. 
  
 (ii) The Selling Shareholder represents and
warrants that: 
  
 a. Authorization; Enforcement;
Validity. The Selling Shareholder is the lawful owner of the Secondary Shares to be sold by the Selling Shareholder hereunder and, upon payment by the Buyers therefor, will convey to the Buyers good and marketable title to such Secondary Shares,
free and clear of all liens, encumbrances, equities and claims whatsoever. The Selling Shareholder has the requisite power and authority to enter into and perform its obligations under this Agreement in accordance with the terms hereof. This
Agreement has been duly executed and delivered by the Selling Shareholder and constitutes its legal, valid and binding obligations, enforceable against it in accordance with its terms, except as such enforceability may be limited by general
principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies. 
  
 b. No Conflicts. The execution, delivery and performance of this
Agreement by the Selling Shareholder and the consummation by the Selling Shareholder of the transactions contemplated hereby will not: (i) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a
default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material agreement, indenture or instrument to which the Selling Shareholder is a party, or (ii) result in a violation of any law, rule,
regulation, order, judgment or decree (including federal and state securities laws and regulations and the rules and regulations of the Principal Market) applicable to the Selling Shareholder or by which any property or asset of the Selling
Shareholder is bound or affected. 
  

 -15- 








 c. Consents. The Selling Shareholder is not required to obtain any consent, authorization or order
of, or make any filing or registration with, any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for such party to execute, deliver or perform any of its obligations under or contemplated by this
Agreement, in each case in accordance with the terms hereof. 
  
 d. Acknowledgment Regarding Buyers’ Purchase of Securities. The Selling Shareholder acknowledges and agrees that each Buyer is acting solely in the capacity of arm’s length purchaser with respect to the Transaction
Documents and the transactions contemplated hereby and thereby. The Selling Shareholder further represents to each Buyer that its respective decisions to enter into this Agreement has been based solely on its respective evaluations. 
  
 e. Absence of Litigation. There is no action, suit, claim, proceeding
or (to the knowledge of the Selling Shareholder) inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Selling Shareholder, threatened against or
affecting the Selling Shareholder that could, individually or in the aggregate, have any affect on the ability of the Selling Shareholder to perform its obligations pursuant to the transactions contemplated by this Agreement. 
  
 f. No Brokers. The Selling Shareholder has taken no action that would
give rise to any claim by any person for brokerage commissions, finder’s fees or similar payments relating to this Agreement or the transactions contemplated hereby, except with respect to Thomas Weisel Partners, whose commissions and fees with
respect to the Common Shares will not be paid for by the Buyers. 
  
 g. Information. The Selling Shareholder has not provided any of the Buyers with any material, non-public information regarding the Company, including, the Company’s businesses, projections and results of operations. 

 
 h. Selling Shareholder Status. The Selling Shareholder (a) is a
sophisticated person with respect to the sale of the Secondary Shares; (b) has adequate information concerning the business and financial condition of the Company to make an informed decision regarding the sale of the Secondary Shares; and (c) has
independently and without reliance upon the Buyer, and based on such information as the Selling Shareholder has deemed appropriate, made its own analysis and decision to enter into this Agreement, except that the Selling Shareholder has relied upon
the Buyer’s express representations, warranties and covenants in this Agreement. The Selling Shareholder acknowledges that the Buyers have not given it any investment advice, credit information or opinion on whether the sale of the Secondary
Shares is prudent. 
  

 -16- 








 4. COVENANTS. 
  
 a. Best Efforts. Each party shall use its best efforts timely to satisfy each of the covenants and the conditions to
be satisfied by it as provided in Sections 5, 6 and 7 of this Agreement. 
  
 b. Form D and Blue Sky. The Company agrees to file a Form D with respect to the Securities as required under Regulation D following the Closing Date and to provide a copy thereof to each Buyer upon request. The
Company, on or before the Closing Date, shall take such other action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities for sale to the Buyers at the Closing pursuant to this
Agreement under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Buyers on or prior to the
Closing Date. The Company shall make all filings and reports relating to the offer and sale of the Securities required under applicable securities or “Blue Sky” laws of the states of the United States following the Closing Date.

  
 c. Reporting Status. Until the date on which the
Investors (as defined in the Registration Rights Agreement) shall have sold all the Common Shares and Additional Investment Right Shares and none of the Additional Investment Rights is outstanding (the “Reporting Period”), the
Company shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and
regulations thereunder would otherwise permit such termination. 
  
 d. Use of Proceeds. The Company will use the proceeds from the sale of the Primary Shares and any Additional Investment Right Shares for working capital purposes and not for the redemption or repurchase of any of its equity
securities. 
  
 e. Financial Information. The Company
agrees to send the following to each Investor during the Reporting Period (i) unless the following are filed with the SEC through EDGAR and are available to the public through the EDGAR system, within one (1) Business Day after the filing thereof
with the SEC, a copy of its Annual Reports on Form 10-K, its Quarterly Reports on Form 10-Q, any Current Reports on Form 8-K and any registration statements (other than on Form S-8) or amendments filed pursuant to the 1933 Act, (ii) on the same day
as the release thereof, electronic copies of all press releases issued by the Company or any of its Subsidiaries (provided that the Investor has provided the Company with an electronic mail address to which such press releases may be sent for this
purpose), and (iii) copies of any notices and other information made available or given to the stockholders of the Company generally, contemporaneously with the making available or giving thereof to the stockholders. As used herein,
“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York or the city of Deerfield Beach, Florida are authorized or required by law to remain closed. 
  
 f. Listing. The Company shall promptly secure the listing of all of
the Registrable Securities (as defined in the Registration Rights Agreement) upon each national securities exchange and automated quotation system, if any, upon which shares of Common 
  

 -17- 








 Stock are then listed (subject to official notice of issuance) and shall maintain, so long as any other shares of Common
Stock shall be so listed, such listing of all Registrable Securities from time to time issuable under the terms of the Transaction Documents. The Company shall use its best efforts to maintain the Common Stock’s authorization for listing on the
Principal Market or on any of the Nasdaq National Market, the New York Stock Exchange or the American Stock Exchange (either, an “Alternate Market”) for so long as it is eligible. Neither the Company nor any of its Subsidiaries
shall take any action without the approval of its shareholders which would be reasonably expected to result in the delisting or suspension of the Common Stock on the Principal Market (except for moves to an Alternate Market). The Company shall pay
all fees and expenses in connection with satisfying its obligations under this Section 4(f). 
  
 g. Fees. At the Closing, the Company shall pay an expense allowance of $20,000 to Portside Growth and Opportunity Fund (a Buyer) or its designee(s), which amount shall be withheld by such Buyer from its
Purchase Price at the Closing. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or broker’s commissions (other than for Persons engaged by any Buyer) relating to or arising out of the
transactions contemplated hereby, including, without limitation, any fees or commissions payable to the Agent. The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable
attorney’s fees and out-of-pocket expenses) arising in connection with any claim relating to any such payment. Except as otherwise set forth in this Agreement or in the Transaction Documents, each party to this Agreement shall bear its own
expenses in connection with the sale of the Securities to the Buyers. 
  
 h. Pledge of Securities. The Company acknowledges and agrees that the Securities may be pledged by an Investor (as defined in the Registration Rights Agreement) in connection with a bona fide margin agreement or other loan or
financing arrangement that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Investor effecting a pledge of Securities shall be required to provide the
Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document, including, without limitation, Section 2(f) of this Agreement; provided that an Investor and its pledgee
shall be required to comply with the provisions of Section 2(f) of this Agreement in order to effect a sale, transfer or assignment of Securities to such pledgee. The Company hereby agrees to execute and deliver such documentation as a pledgee of
the Securities may reasonably request in connection with a pledge of the Securities to such pledgee by an Investor. 
  
 i. Disclosure of Transactions and Other Material Information. The Company shall, on or before 8:30 a.m., New York City Time, on first Business Day
after execution of this Agreement, issue a press release reasonably acceptable to the Buyers disclosing all material terms of the transactions contemplated hereby. On or before 8:30 a.m., New York City Time, on the second Business Day following the
date of execution of this Agreement, the Company shall file a Current Report on Form 8-K describing the terms of the transactions contemplated by the Transaction Documents in the form required by the 1934 Act, and attaching the material Transaction
Documents (including, without limitation, this Agreement (but not the schedules to this Agreement), the form of Additional Investment Right and the Registration Rights Agreement) as exhibits to such filing (such filing including all attachments, the
“8-K 
  

 -18- 








 Filing”). The Company shall not, and shall cause each of its Subsidiaries and each of their respective
officers, directors, employees and agents, not to, provide any Buyer with any material, nonpublic information regarding the Company or any of its Subsidiaries from and after the filing of the press release referred to in the first sentence of this
Section without the express written consent of such Buyer. In the event that the Company in writing requests any Buyer to enter into a written confidentiality agreement regarding information which the Company believes is material and non-public, and
such Buyer informs the Company that it would not be willing to enter into such confidentiality agreement, then such Buyer shall be deemed to have waived its rights under Section 4(m) below with respect to any Subsequent Placement that is the subject
of such request. In the event of a breach of the foregoing covenant by the Company, any Subsidiary, or its each of respective officers, directors, employees and agents, in addition to any other remedy provided herein or in the Transaction
Documents, a Buyer shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, nonpublic information without the prior approval by the Company, its Subsidiaries, or any of
its or their respective officers, directors, employees or agents. No Buyer shall have any liability to the Company, its Subsidiaries, or any of its or their respective officers, directors, employees, shareholders or agents for any such disclosure.
Subject to the foregoing, neither the Company nor any Buyer shall issue any press releases or any other public statements with respect to the transactions contemplated hereby; provided, however, that the Company shall be entitled,
without the prior approval of any Buyer, to make any press release or other public disclosure with respect to such transactions (i) in substantial conformity with the 8-K Filing and contemporaneously therewith and (ii) as is required by applicable
law and regulations, including the applicable rules and regulations of the Principal Market (provided that in the case of clause (i) each Buyer shall be consulted by the Company in connection with any such press release or other public disclosure
prior to its release). 
  
 j. Additional Registration
Statements. Until the date that the Registration Statement (as defined in the Registration Rights Agreement) is first declared effective by the SEC (the “Effective Date”), the Company will not file a registration statement under
the 1933 Act relating to securities that are not the Securities. 
  
 k. Corporate Existence. So long as any Buyer beneficially owns any Additional Investment Rights, the Company shall maintain its corporate existence and shall not sell all or substantially all of the Company’s assets, except in
the event of a merger or consolidation or sale of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i) assumes the Company’s obligations hereunder and under the agreements and
instruments entered into in connection herewith and (ii) is a publicly traded corporation whose common stock is quoted on or listed for trading on the Principal Market, the New York Stock Exchange or the American Stock Exchange. 
  
 l. Reservation of Shares. The Company shall take all action necessary
to at all times have authorized, and reserved for the purpose of issuance, from and after the Closing Date, the number of shares of Common Stock issuable upon exercise of the Additional Investment Rights being issued at the Closing in conformity
with Section 3(c). 
  

 -19- 








 m. Additional Issuances of Securities. 
  
 (i) For purposes of this Section 4(m), the following definitions shall
apply. 
  
 (1) “Common Stock Equivalents”
means, collectively, Options and Convertible Securities. 
  
 (2)
“Convertible Securities” means any stock or securities (other than Options) convertible into or exercisable or exchangeable for Common Stock. 
  

(3) “Options” means any rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities. 

 
 (4) “Trading Day” means any day on which the Common
Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded; provided that
“Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such
exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00 p.m., New York City Time). 
  
 (ii) From the date hereof until the date that is five (5) Trading Days
following the Expiration Date (as defined in the Additional Investment Rights) (the “Trigger Date”), the Company will not, directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any
offer, sale, grant or any option to purchase or other disposition of) any of its or its Subsidiaries’ equity or equity equivalent securities, including without limitation any debt, preferred stock or other instrument or security that is, at any
time during its life and under any circumstances, convertible into or exchangeable or exercisable for Common Stock or Common Stock Equivalents (any such offer, sale, grant, disposition or announcement being referred to as a “Subsequent
Placement”). 
  
 (iii) From the Trigger Date until the
first anniversary of the Closing Date, the Company will not, directly or indirectly, effect any Subsequent Placement unless the Company shall have first complied with this Section 4(m)(iii). 
  
 (1) The Company shall deliver to each Buyer a written notice (the
“Offer Notice”) of any proposed or intended issuance or sale or exchange (the “Offer”) of the securities being offered (the “Offered Securities”) in a Subsequent Placement, which Offer Notice shall
(w) identify and describe the Offered Securities, (x) describe the price and other material terms upon which they are to be issued, sold or exchanged, and the number or amount of the Offered Securities to be issued, sold or exchanged, (y) identify
the persons or entities (if known) to which or with which the Offered Securities are to be offered, issued, sold or exchanged and (z) offer to issue and sell to or exchange with the Buyers not less than the greater of (i) one-third of the Offered
Securities and (ii) Offered Securities representing $5,000,000, allocated among the Buyers (a) based on such Buyer’s pro rata portion of the number of 
  

 -20- 








 Common Shares purchased hereunder (the “Basic Amount”), and (b) with respect to each Buyer that elects
to purchase its Basic Amount, any additional portion of the Offered Securities attributable to the Basic Amounts of other Buyers as such Buyer shall indicate it will purchase or acquire should the other Buyers subscribe for less than their Basic
Amounts (the “Undersubscription Amount”). 
  
 (2) To accept an Offer, in whole or in part, a Buyer must deliver a written notice to the Company prior to the end of the fifth (5th) Business Day after such Buyer’s receipt of the Offer Notice (the “Offer Period”), setting forth the portion of the Buyer’s Basic Amount that such Buyer elects to purchase and, if such Buyer shall
elect to purchase all of its Basic Amount, the Undersubscription Amount, if any, that such Buyer elects to purchase (in either case, the “Notice of Acceptance”). If the Basic Amounts subscribed for by all Buyers are less than the
total of all of the Basic Amounts, then each Buyer who has set forth an Undersubscription Amount in its Notice of Acceptance shall be entitled to purchase, in addition to the Basic Amounts subscribed for, the Undersubscription Amount it has
subscribed for; provided, however, that if the Undersubscription Amounts subscribed for exceed the difference between the total of all the Basic Amounts and the Basic Amounts subscribed for (the “Available Undersubscription
Amount”), each Buyer who has subscribed for any Undersubscription Amount shall be entitled to purchase only that portion of the Available Undersubscription Amount as the Basic Amount of such Buyer bears to the total Basic Amounts of all
Buyers that have subscribed for Undersubscription Amounts, subject to rounding by the Company to the extent its deems reasonably necessary. 
  
 (3) The Company shall have thirty (30) days from the expiration of the Offer Period above to offer, issue, sell or exchange all or any part of such
Offered Securities as to which a Notice of Acceptance has not been given by the Buyers (the “Refused Securities”), but only to the offerees described in the Offer Notice (if so described therein) and only upon terms and conditions
(including, without limitation, unit prices and interest rates) that are not more favorable to the acquiring person or persons or less favorable to the Company than those set forth in the Offer Notice. 
  
 (4) In the event the Company shall propose to sell less than all the Refused
Securities (any such sale to be in the manner and on the terms specified in Section 4(m)(iii)(3) above), then each Buyer, at its sole option and in its sole discretion, may reduce the number or amount of the Offered Securities specified in its
Notice of Acceptance to an amount that shall be not less than the number or amount of the Offered Securities that the Buyer elected to purchase pursuant to Section 4(m)(iii)(2) above multiplied by a fraction, (i) the numerator of which shall be the
number or amount of Offered Securities the Company actually proposes to issue, sell or exchange (including Offered Securities to be issued or sold to Buyers pursuant to Section 4(m)(iii)(3) above prior to such reduction) and (ii) the denominator of
which shall be the original amount of the Offered Securities. In the event that any Buyer so elects to reduce the number or amount of Offered Securities specified in its Notice of Acceptance, the Company may not issue, sell or exchange more than the
reduced number or amount of the Offered Securities unless and until such securities have again been offered to the Buyers in accordance with Section 4(m)(iii)(1) above. 
  

 -21- 








 (5) Upon the closing of the issuance, sale or exchange of all or less than all of the Refused
Securities, the Buyers shall acquire from the Company, and the Company shall issue to the Buyers, the number or amount of Offered Securities specified in the Notices of Acceptance, as reduced pursuant to Section 4(m)(iii)(4) above if the Buyers have
so elected, upon the terms and conditions specified in the Offer. The purchase by the Buyers of any Offered Securities is subject in all cases to the preparation, execution and delivery by the Company and the Buyers of a purchase agreement relating
to such Offered Securities reasonably satisfactory in form and substance to the Buyers and their respective counsel. 
  
 (6) Any Offered Securities not acquired by the Buyers or other Persons in accordance with Section 4(m)(iii)(3) above may not be issued, sold or exchanged
until they are again offered to the Buyers under the procedures specified in this Agreement. 
  
 (iv) The restrictions contained in subsections (ii) and (iii) of this Section 4(m) shall not apply (1) in connection with any employee benefit plan which has been approved by the Board of Directors of the Company,
pursuant to which the Company’s securities may be issued to any employee, officer or director for services provided to the Company or any of its Subsidiaries, or pursuant to the exercise of any securities of the Company issued thereunder; (2)
upon exercise of the Additional Investment Rights; (3) pursuant to a bona fide firm commitment underwritten public offering with a nationally recognized underwriter which generates gross proceeds to the Company in excess of $30,000,000 (other than
an “at-the-market offering” as defined in Rule 415(a)(4) under the 1933 Act and “equity lines”); (4) upon conversion of any Options or Convertible Securities that are outstanding on the day immediately preceding the Closing Date,
provided, that the terms of such Options or Convertible Securities are not amended, modified or changed on or after the Closing Date; or (5) in connection with a bona fide transaction in which the Company issues Common Stock or Common Stock
Equivalents to a Person in which the Company receives benefits in addition to the investment of funds, which shall include a strategic acquisition, but which shall not include a transaction in which the Company is issuing securities primarily for
the purpose of raising capital or to an entity the primary business of which is investing in securities (unless in connection with a strategic acquisition with an operating company in which an entity the primary business of which is investing in
securities is a stockholder). 
  
 5. TRANSFER RESTRICTIONS;
TRANSFER AGENT INSTRUCTIONS. 
  
 a. Transfer
Restrictions. The legend set forth in Section 2(g) shall be removed and the Company shall issue a certificate without such legend or any other legend to the holder of the applicable Securities upon which it is stamped, if (i) such Securities are
registered for resale under the 1933 Act, (ii) in connection with a sale, assignment or other transfer, such holder provides the Company with an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such sale,
assignment or transfer of such Securities may be made without registration under the applicable requirements of the 1933 Act, or (iii) such holder provides the Company with reasonable assurance that such Securities can be sold, assigned or
transferred pursuant to Rule 144. The Company shall cause Company Counsel (as defined below) to issue the legal notice included in the Irrevocable Transfer Agent Instructions to the Company’s transfer agent on the Effective Date. Following the
Effective Date or at such earlier time as a legend is no longer required for certain Securities, the Company will no later than three 
  

 -22- 








 Business Days following the delivery by a Buyer to the Company or the Company’s transfer agent of a legended
certificate representing such Securities, deliver or cause to be delivered to such Buyer a certificate representing such Securities that is free from all restrictive and other legends. Following the Effective Date and upon the delivery to any Buyer
of any certificate representing Securities that is free from all restrictive and other legends, such Buyer agrees that any sale of such Securities shall be made pursuant to the Registration Statement and in accordance with the plan of distribution
described therein and the prospectus delivery requirements of the 1933 Act, or pursuant to an available exemption from the registration requirements of the 1933 Act. The Company may not make any notation on its records or give instructions to any
transfer agent of the Company that enlarge the restrictions on transfer set forth in Section 2(g). 
  
 b. Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent, and any subsequent transfer agent, to issue
certificates or credit shares to the applicable balance accounts at The Depository Trust Company (“DTC”), registered in the name of each Buyer or its respective nominee(s), for the Additional Investment Right Shares in such amounts
as specified from time to time by each Buyer to the Company upon exercise of the Additional Investment Rights in the form of Exhibit C attached hereto (the “Irrevocable Transfer Agent Instructions”). The Company represents
and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5, and stop transfer instructions to give effect to Section 2(f) hereof, will be given by the Company to its transfer agent with
respect to the Securities, and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the other Transaction Documents. 
  
 c. Breach. The Company acknowledges that a breach by it of its
obligations hereunder will cause irreparable harm to a Buyer. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5 will be inadequate and agrees, in the event of a breach or threatened
breach by the Company of the provisions of this Section 5, that a Buyer shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the
necessity of showing economic loss and without any bond or other security being required. 
  
 6. CONDITIONS TO THE COMPANY’S AND SELLING SHAREHOLDER’S OBLIGATION TO SELL. 
  
 The obligation of the Company hereunder to issue and sell the Common Shares and the related Additional Investment Rights, and of the Selling Shareholder
to sell the Common Shares being sold by such shareholder, to each Buyer at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Company’s and
the Selling Shareholder’s benefit and may be waived by the Company and the Selling Shareholder at any time in their sole discretion by providing each Buyer with prior written notice thereof: 
  
 (i) Each Buyer shall have executed each of the Transaction Documents to
which it is a party and delivered the same to the Company. 
  

 -23- 








 (ii) Each Buyer shall have delivered to the Company the Purchase Price for the Primary Shares and the
related Additional Investment Rights being purchased from the Company by such Buyer at the Closing by wire transfer of immediately available funds pursuant to the wire instructions provided by the Company. 
  
 (iii) Each Buyer shall have delivered to the Company (for the benefit of the
Selling Shareholder) the Purchase Price for the Secondary Shares being purchased from the Selling Shareholder to such Buyer at the Closing by wire transfer of immediately available funds pursuant to the wire instructions provided by the Company.

  
 (iv) The representations and warranties of each Buyer shall be
true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date), and such Buyer shall have performed, satisfied
and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by such Buyer at or prior to the Closing Date. 
  
 7. CONDITIONS TO EACH BUYER’S OBLIGATION TO PURCHASE. 

 
 The obligation of each Buyer hereunder to purchase the Common Shares and
the related Additional Investment Rights at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for each Buyer’s sole benefit and may be waived by
such Buyer at any time in its sole discretion by providing the Company and the Selling Shareholder with prior written notice thereof, and provided that any delivery of a document or instrument to any and all Buyers required below may be considered
made by delivery of the same to Schulte Roth & Zabel LLP, as counsel to lead investor, at its offices specified in Section 1(a): 
  
 (i) The Company and the Selling Shareholder shall have executed and delivered to such Buyer (i) each of the Transaction Documents to which they are a
party and (ii) the Common Shares (in such amounts as such Buyer shall request) and the related Additional Investment Rights (in such amounts as such Buyer shall request) being purchased by such Buyer at the Closing pursuant to this Agreement.

  
 (ii) Such Buyer shall have received the opinion of Edwards
& Angell LLP, outside counsel to the Company and to the Selling Shareholder (“Company Counsel”), dated as of the Closing Date, in substantially the form of Exhibit D attached hereto. 
  
 (iii) The Company shall have delivered to such Buyer a copy of the
Irrevocable Transfer Agent Instructions, in the form of Exhibit C attached hereto, which instructions shall have been delivered to and acknowledged in writing by the Company’s transfer agent. 
  
 (iv) The Company shall have delivered to such Buyer a certificate evidencing
the incorporation and good standing of the Company and each of its U.S. subsidiaries in its state of incorporation issued by the Secretary of State of such state of incorporation as of a date within 10 days of the Closing Date. 
  

 -24- 








 (v) The Common Stock (I) shall be authorized for quotation or listed on the Principal Market and (II)
shall not have been suspended, as of the Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension by the SEC or the Principal Market have been threatened, as of the Closing Date, either (A) in
writing by the SEC or the Principal Market or (B) by falling below the minimum listing maintenance requirements of the Principal Market. 
  
 (vi) The Company shall have delivered to such Buyer a certified copy of the Certificate of Incorporation as certified by the Secretary of State of the
State of Delaware within 10 days of the Closing Date. 
  
 (vii)
The Company shall have delivered to such Buyer a certificate, executed by the Secretary of the Company and dated as of the Closing Date, as to (i) the resolutions consistent with Section 3(b) as adopted by the Company’s Board of Directors in a
form reasonably acceptable to such Buyer, (ii) the Certificate of Incorporation and (iii) the Bylaws, each as in effect at the Closing, in the form attached hereto as Exhibit E. 
  
 (viii) The representations and warranties of the Company shall be true and correct as of the date when made and as of the
Closing Date as though made at that time (except for representations and warranties that speak as of a specific date) and the Company shall have performed, satisfied and complied in all respects with the covenants, agreements and conditions required
by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Closing Date. Such Buyer shall have received a certificate, executed by the Chief Executive Officer of the Company, dated as of the Closing
Date, to the foregoing effect and as to such other matters as may be reasonably requested by such Buyer in the form attached hereto as Exhibit F. 
  
 (ix) The Company shall have delivered to such Buyer a letter from the Company’s transfer agent certifying the number of shares of Common Stock
outstanding as of a date within five days of the Closing Date. 
  
 (x) The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the sale of the Common Shares and the Additional Investment Rights. 
  
 (xi) The Company shall have delivered to such Buyer such other documents
relating to the transactions contemplated by this Agreement as such Buyer or its counsel may reasonably request. 
  

 -25- 








 8. TERMINATION. In the event that the Closing shall not have occurred with respect to a Buyer on
or before five (5) Business Days from the date hereof due to the Company’s or such Buyer’s failure to satisfy the conditions set forth in Sections 6 and 7 above (and the nonbreaching party’s failure to waive such unsatisfied
condition(s)), the nonbreaching party shall have the option to terminate this Agreement with respect to such breaching party at the close of business on such date without liability of any party to any other party. 
  
 9. MISCELLANEOUS. 
  
 a. Governing Law; Jurisdiction; Jury Trial. All questions concerning
the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the non-exclusive jurisdiction of the state and federal courts sitting
in The City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. 
  
 b. Counterparts. This Agreement may be executed in two or more
identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile signature. 
  
 c. Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement. 
  
 d. Severability. If any provision of this
Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any
provision of this Agreement in any other jurisdiction. 
  

 -26- 








 e. Entire Agreement; Amendments. This Agreement supersedes all other prior oral or written
agreements between the Buyers, the Selling Shareholder, the Company, their affiliates and Persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the instruments referenced herein contain the entire
understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, none of the Company, the Selling Shareholder nor any Buyer makes any representation, warranty, covenant or
undertaking with respect to such matters. No provision of this Agreement may be amended other than by an instrument in writing signed by the Company, the Selling Shareholder and the holders of Common Shares representing at least a majority of the
amount of the Common Shares, or, if prior to the Closing Date, the Buyers listed on the Schedule of Buyers as being obligated to purchase at least a majority of the amount of the Common Shares. No provision hereof may be waived other than by an
instrument in writing signed by the party against whom enforcement is sought. No such amendment shall be effective to the extent that it applies to less than all of the holders of the Common Shares then outstanding. No consideration shall be offered
or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration also is offered to all of the parties to the Transaction Documents, holders of Common Shares or
holders of the Additional Investment Rights, as the case may be. The Company has not, directly or indirectly, made any agreements with any Buyers relating to the terms or conditions of the transactions contemplated by the Transaction Documents
except as set forth in the Transaction Documents. 
  
 f.
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally;
(ii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) one Business Day after deposit with an overnight courier service, in each
case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications shall be: 
  
 If to the Company or the Selling Shareholder: 
  
 eDiets.com, Inc. 
 3801 W. Hillsboro Boulevard

 Deerfield Beach, Florida 33442 
 Telephone:    (954) 360-9022 
 Facsimile:      (954) 570-9041 
 Attention:      Chief Financial Officer 
  
 with a copy to: 
  
 Edwards & Angell LLP 
 350 East Las Olas
Boulevard, Suite 1150 
 Fort Lauderdale, FL 33301 
 Telephone:    (954) 667-6129 
 Facsimile:      (954)
727-2601 
 Attention:      Leslie J. Croland 
  

 -27- 








 If to the Transfer Agent: 
  
 American Stock Transfer and Trust Company 
 6201 15th Avenue, 3rd Floor 
 Brooklyn, NY 11219 
 Facsimile:    (718) 921-8336 
 Attention:    Carlos Pinto 
  
 If to a Buyer, to its
address and facsimile number set forth on the Schedule of Buyers, with copies to such Buyer’s representatives as set forth on the Schedule of Buyers, or to such other address and/or facsimile number and/or to the attention of such other Person
as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other
communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided by an overnight courier
service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively. 
  
 g. Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the parties and their respective successors and assigns, including any purchasers of the Common Shares or the Additional Investment Rights pursuant to a transaction not on the Principal Market or any Alternate Market. The
Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the holders of Common Shares representing at least a majority of the number of the Common Shares, including by merger or
consolidation. A Buyer may assign some or all of its rights hereunder without the consent of the Company. 
  
 h. No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 
  
 i. Survival. Unless this Agreement is terminated under Section 8, the representations and warranties of the Company and the Buyers contained in
Sections 2 and 3, the agreements and covenants set forth in Sections 4, 5 and 9 shall survive the Closing and the delivery and exercise of Securities, as applicable. Each Buyer shall be responsible only for its own representations, warranties,
agreements and covenants hereunder. 
  
 j. Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. 
  
 k. Indemnification. In consideration of each Buyer’s execution and delivery of this Agreement and acquiring the Securities hereunder and in
addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, 
  

 -28- 








 protect, indemnify and hold harmless each Buyer and each other holder of the Securities and all of their stockholders,
partners, members, officers, directors, employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated
by this Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective
of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a
result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (b)
any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby or (c) any cause of action, suit or claim brought or made
against such Indemnitee by a third party (including for these purposes a derivative action brought on behalf of the Company) and arising out of or resulting from (i) the execution, delivery, performance or enforcement of the Transaction Documents or
any other certificate, instrument or document contemplated hereby or thereby, (ii) any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, or (iii) the status of
such Buyer or holder of the Securities as an investor in the Company (except, in the case of this clause (iii), arising from a Person who is, directly or indirectly, an investor, partner or equityholder in the Buyer in such Person’s capacity as
such an investor, partner or equityholder, or arising in relation to the Buyer’s capacity to make an investment in the Company). To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall
make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. Except as otherwise set forth herein, the mechanics and procedures with respect to the rights and
obligations under this Section 9(k) shall be the same as those set forth in Section 6 of the Registration Rights Agreement. 
  
 l. No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party. 
  
 m. Remedies. Each Buyer and each holder of the Securities shall have all rights and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time
under any other agreement or contract and all of the rights which such holders have under any law. Any Person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or
other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company recognizes that in the event that it fails to perform, observe, or discharge any
or all of its obligations under the Transaction Documents, any remedy at law may prove to be inadequate relief to the Buyers. The Company therefore agrees that the Buyers shall be entitled to seek temporary and permanent injunctive relief in any
such case without the necessity of proving actual damages and without posting a bond or other security. 
  

 -29- 








 n. Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and
without limiting any similar provisions of) the Transaction Documents, whenever any Buyer exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods
therein provided, then such Buyer may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights

  
 o. Payment Set Aside. To the extent that the Company
makes a payment or payments to the Buyers hereunder or pursuant to any of the other Transaction Documents or the Buyers enforce or exercise their rights hereunder or thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any
other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be
satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. 
  
 p. Independent Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under any Transaction Document are several and not
joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document, and
no action taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Buyers are in any way acting in concert
or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Buyer confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its
own counsel and advisors. Each Buyer shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall not be necessary
for any other Buyer to be joined as an additional party in any proceeding for such purpose. 
  
 [Signature Page Follows] 
  

 -30- 








 IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	 COMPANY:
 EDIETS.COM,
INC.

		
	 By:
	 	  


	 Name:
	 	 
	 Title:
	 	 
	
	 SELLING SHAREHOLDER:

	
	

	 DAVID R. HUMBLE



  

 [Signature Page to Securities Purchase Agreement] 








 IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	
	 PORTSIDE GROWTH AND OPPORTUNITY FUND

		
	 By:
	 	 Ramius Capital Group, LLC

	 Its:
	 	 Investment Adviser

		
	 By:
	 	  


	 Name:
	 	 
	 Title:
	 	 


  

 [Signature Page to Securities Purchase Agreement] 








 IN WITNESS WHEREOF, each Buyer and the Company have caused this Securities Purchase Agreement to
be duly executed as of the date first written above. 
  

			
	BUYER:
	
	[OTHERS]
		
	 By:
	 	  


	 Name:
	 	 
	 Title:
	 	 


  

 [Signature Page to Securities Purchase Agreement] 








 SCHEDULE OF BUYERS 
  

													
	(1)	  	(2)	  	(3)	  	(4)	  	(5)	  	(6)	  	(7)
							
	 Buyer

	  	Address and Facsimile Number

	  	Number of
Primary
Shares

	  	Number of
Additional
Investment
Right
Shares

	  	Number of
Secondary
Shares

	  	Purchase Price

	  	Legal Representative’s
Address and Facsimile Number


	Portside Growth and Opportunity Fund	  	c/o Ramius Capital Group, L.L.C.
666 Third Avenue,
26th Floor
New York,
NY 10017
Attention: Jeffrey Smith
                  Roger
Anscher
Telephone: (212) 845-7955
Fax: (212) 845-7999
Residence: Cayman Islands	  	385,785	  	132,614	  	144,670	  	$4.40	  	Schulte, Roth & Zabel LLP
919 Third Avenue
New York, NY 10022
Attn: Eleazer Klein, Esq.
Telephone: (212)
756-2000
Fax: (212) 593-5955
							
	SF Capital Partners Ltd.	  	3600 South Lake Drive
St. Francis, WI 53235
Attention: Brian Davidson
                  Dan McNally
Telephone: (414) 294-7587
Fax: (414) 294-4487	  	181,818	  	62,500	  	68,182	  	$4.40	  	 
							
	Gemini Master Fund, Ltd.	  	c/o Gemini Investment
Strategies, LLC
35 Waterview Boulevard
Parsippany, NJ 07054
Attention: Steven Winters
Telephone: (973) 404-1350
Fax: (973) 404-1360
Residence: Cayman
Islands	  	5,455	  	1,875	  	2,045	  	$4.40	  	Duval & Stachenfeld, LLP
300 East 42nd Street
New York, NY 10017
Attn: Bob Mazzeo, Esq.
Telephone: (212) 692-5530
Fax: (212)
883-8883
							
	Provident Premier Master Fund, Ltd.	  	c/o Gemini Investment
Strategies, LLC
35 Waterview Boulevard
Parsippany, NJ 07054
Attention: Steven Winters
Telephone: (973) 404-1350
Fax: (973) 404-1360
Residence: Cayman
Islands	  	78,182	  	26,875	  	29,318	  	$4.40	  	Duval & Stachenfeld, LLP
300 East 42nd Street
New York, NY 10017
Attn: Bob Mazzeo, Esq.
Telephone: (212) 692-5530
Fax:
(212) 883-8883









													
	(1)	  	(2)	  	(3)	  	(4)	  	(5)	  	(6)	  	(7)
							
	 Buyer

	  	Address and Facsimile Number

	  	Number
of
Primary
Shares

	  	Number of
Additional
Investment
Right
Shares

	  	Number of
Secondary
Shares

	  	Purchase Price

	  	Legal Representative’s
Address and Facsimile Number


	Langley Partners, L.P.	  	c/o Langley Management, LLC
535 Madison Avenue
7th Floor
New York, NY 10022
Attention: Jeffrey Thorp
Telephone: (212) 850-7528
Fax: (212) 208-2971	  	83,636	  	28,750	  	31,364	  	$4.40	  	 
							
	UBS O’Connor LLC F/B/O O’Connor PIPES Corporate Strategies Master Ltd.	  	c/o UBS O’Connor LLC
One North Wacker Drive
32nd Floor
Chicago, IL 60606 Attention:
Timothy Goldenman
Telephone: (312) 525-5868
Fax: (312) 525-6271	  	116,364	  	40,000	  	43,636	  	$4.40	  	 
							
	Elliott International, L.P.	  	c/o Elliott Management Corporation
712 5th Avenue, 35th Floor
New York, NY
10019
Attention: Elliot Greenberg
                  Brett
Cohen
                  Nadav Manham
Telephone: (212)
506-2999
Fax: (212) 974-2092
Residence: Cayman Islands	  	165,289	  	56,818	  	61,983	  	$4.40	  	Kleinberg, Kaplan, Wolff &
Cohen, P.C.
551 5th Avenue
New York, NY
10176
Attn: Laurence Hui
Telephone: (212) 986-6000
Fax: (212) 986-8866
							
	RHP Master Fund, Ltd.	  	c/o Rock Hill Investment
Management, L.P.
3 Bala Plaza – East, Suite 585
Bala Cynwyd,
PA 19004
Attention: Keith Marlowe
                  Kamlesh
Bhatia
Telephone: (610) 949-9700
Fax: (610) 949-9600
Residence: Cayman Islands	  	145,455	  	50,000	  	54,545	  	$4.40	  	 









													
	(1)	  	(2)	  	(3)	  	(4)	  	(5)	  	(6)	  	(7)
							
	 Buyer

	  	Address and Facsimile Number

	  	Number
of
Primary
Shares

	  	Number of
Additional
Investment
Right
Shares

	  	Number of
Secondary
Shares

	  	Purchase Price

	  	Legal Representative’s
Address and Facsimile Number


	 Dalewood Associates, LP
	  	c/o Earlybird Capital
600 Third Avenue, 33rd Floor
New York, NY 10016
Attention: Steve Levine
Telephone: (212) 661-0200
Fax: (212) 661-4936	  	43,636	  	15,000	  	16,364	  	$4.40	  	 
							
	 Cranshire Capital, L.P.
	  	c/o Downsview Capital
666 Dundee Road, Suite 1901
Northbrook, IL 60062
Attention: Mitch
Kopin
                  Keith Goodman
Telephone: (847)
562-9030
Fax: (847) 562-9030
Fax: (847) 562-9031	  	83,636	  	28,750	  	31,364	  	$4.40	  	 
							
	 Topaz Partners
	  	c/o Jemmco Capital Corp
900 Third Avenue 11th Floor
New York, NY 10022
Attention Joseph
Lagnado
Telephone: (212) 821-8705
Fax: (212) 644-1175	  	165,289	  	56,818	  	61,983	  	44.40	  	Akin, Gump
590 Madison Avenue
New York, NY 10022
Attn: Charles
Giggio
Telephone: (212) 872-1010
Fax: (212) 407-3210
							
	 Capital Ventures International
	  	c/o Heights Capital
425 California Street, Suite 1100
San Francisco, CA
94104
Attention: Martin Kobinger
Telephone: (415) 403-6500
Fax: (415) 403-6525	  	145,455	  	50,000	  	54,545	  	$4.40	  	 

  
  

 36 








 EXHIBITS 
  

			
	 Exhibit A
	  	Form of Additional Investment Rights
	 Exhibit B
	  	Form of Registration Rights Agreement
	 Exhibit C
	  	Form of Irrevocable Transfer Agent Instructions
	 Exhibit D
	  	Form of Company Counsel Opinion
	 Exhibit E
	  	Form of Secretary’s Certificate
	 Exhibit F
	  	Form of Officer’s Certificate

  
 SCHEDULES

  

			
	 Schedule 3(a)
	  	Subsidiaries
	 Schedule 3(l)
	  	Absence of Certain Changes
	 Schedule 3(q)
	  	Capitalization
	 Schedule 3(r)
	  	Indebtedness and Other Contracts
	 Schedule 3(w)
	  	Intellectual Property

  

 37